FBFrancoise Boehlen

Francoise Boehlen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francoise Boehlen has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subthalamic nucleus deep brain stimulation for Parkinson's disease in a patient with severe haemophilia A

    by F. Boehlen, P. R. Burkhard, S. Momjian, P. Fontana


  • Open Access

    Restoration of adrenal function after bilateral adrenal damage due to heparin-induced thrombocytopenia (HIT): a case report

    by Jaafar Jaafar, Françoise Boehlen, Jacques Philippe, Mathieu Nendaz

    Patients with bilateral adrenal damage due to heparin-induced thrombocytopenia usually need lifelong steroid substitution. So far, no data exists about the natural evolution of such a condition, especially about adrenal function recovery and the real need for lifelong steroids. An 81-year-old Caucasian woman with bilateral adrenal damage due to heparin-induced thrombocytopenia presented with fever and severe hypotension. Adrenal failure was confirmed biologically and radiologically. She eventually recovered her adrenal function, allowing for steroid withdrawal. This case report addresses the different mechanisms of adrenal damage due to heparin-induced thrombocytopenia and its natural evolution with potential recovery. This should encourage clinicians to evaluate the real necessity for lifelong corticosteroid substitution in such a condition.


  • Outcome measures in haemophilia: a systematic review

    by Françoise Boehlen, Lukas Graf, Erik Berntorp

    Haemophilia A and B are hereditary X‐linked disorders due to deficiency (or absence) of coagulation factor VIII or IX, respectively. Bleeding risk is related to the severity of factor deficiency. Repeated joint bleeding can lead to a severe haemophilic arthropathy resulting in disabilities. Outcome measurements in persons with haemophilia (PWH) have been limited to laboratory evaluation (factor VIII or IX levels) and clinical outcomes (such as bleeding frequency), morbidity (for example linked with arthropathy) and mortality. Due to the new standard of care of PWH, there is a need to consider other outcome measures, such as the early detection and quantification of joint disease, health‐related quality of life (QoL) and economic or cost–utility analyses. To investigate this, we performed a 10‐yr systematic overview of outcome measures in haemophilia. Only clinical trials including at least 20 patients with haemophilia A or B were included. To facilitate the search strategy, eight issues of outcome measures were selected: physical scores, imaging technique scores, functional scores, QoL measurement, mortality, bleeding frequency, cost and outcome and bone mineral density. The results of these will be discussed. Clearly defined outcomes in haemophilia care are important for many reasons, to evaluate new treatments, to justify treatment strategies, to allow a good follow‐up, to perform studies and to allocate resources. The use of such scoring systems is clearly recommended by experts in haemophilia care. However, most centres do not perform such scores outside clinical trials due to reasons such as lack of time and resources.


  • Open Access

    PP129—Time-to-achieve stability of anticoagulation is decreased in ABCB1 mutated patients treated with acenocoumarol

    by V. Rollason, L. Gschwind, Y. Daali, F. Boehlen, M. Rebsamen, C. Combescure, A. Matthey, P. Bonnabry, P. Dayer, J.A. Desmeules

  • Open Access

    OC036—Impact Of Cyp2c9 Polymorphisms On The Vulnerability To Pharmacokinetic Drug–Drug Interactions During Acenocoumarol Treatment

    by V. Rollason, L. Gschwind, F. Boehlen, M. Rebsamen, C. Combescure, M. Grünenwald, A. Matthey, P. Bonnabry, P. Dayer, J.A. Desmeules

    • 6 February 2013
      • Vol. 9  (372) , 315-8, 320

    [Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know].

    by A Casini, F Boehlen, T Lecompte, P De Moerloose

    Polycythaemia vera, essential thrombocythemia and primary myelofibrosis are stem cell-derived clonal haemopathies classified in the group of myeloproliferative neoplasms. Their clinical course may be complicated by both arterial and venous (sometimes in unusual sites) thrombotic events. Although general risk factors contribute to the prevalence of thrombotic events in this population, some other risk factors are specifically associated with the myeloproliferative neoplasms. The treatment options are aspirin, anticoagulation, cytoreduction and phlebotomies.

    • 16 January 2013
      • Vol. 9  (369) , 104-7

    [New oral anticoagulants: from theory to practice].

    by P De Moerloose, A Casini, F Boehlen, Pierre Fontana

    Physicians are confronted with many new antithrombotic drugs, either antiplatelet agents or new oral anticoagulants (NOAC). Targets of NOAC are specific (either anti-IIa or antiXa) and clinical studies have shown that NOAC are as efficacious and as safe as "old" anticoagulants (heparin, low molecular weight heparin, vitamin K antagonists); moreover they present some advantages. Indeed, NOAC have a wide therapeutic window and do not require laboratory monitoring. Therefore, it is very tempting to prescribe them on a large scale basis in patients at risk or having thromboembolic diseases. However, things are not so simple in the day-to-day practice and this review aims at answering in a brief and simplified manner to some questions.

  • P146 TLR2-ligands induce NF-κB activation exclusively from endosomal compartments

    by K.J. Brandt, C. Fickentscher, G. Frizon de Lamotte, F. Boehlen, G. Reber, E.K. Kruithof, P. de Moerloose

  • Identification and weighting of the most critical “real-life” drug–drug interactions with acenocoumarol in a tertiary care hospital

    by L. Gschwind, V. Rollason, C. Lovis, F. Boehlen, P. Bonnabry, P. Dayer, J. A. Desmeules

    Purpose The objective of this study was to identify the most clinically relevant drug–drug interactions (DDIs) at risk of affecting acenocoumarol safety in our tertiary care university hospital, a 2,000 bed institution. Methods We identified DDIs occurring with acenocoumarol by combining two different sources of information: a 1-year retrospective analysis of acenocoumarol prescriptions and comedications from our Computerized Physician Order Entry (CPOE) system (n = 2,439 hospitalizations) and a retrospective study of clinical pharmacology consultations involving acenocoumarol over the past 14 years (1994–2007) (n = 407). We classified these DDIs using an original risk-analysis method. A criticality index was calculated for each associated drug by multiplying three scores based on mechanism of interaction, involvement in a supratherapeutic international normalized ratio (INR) (≥ 6) and involvement in a severe bleeding. Results One hundred and twenty-six DDIs were identified and weighted. Twenty-eight drugs had a criticality index ≥ 20 and were therefore considered at high risk for interacting with acenocoumarol by increasing its effect: 75% of these drugs involved a pharmacokinetic mechanism and 14 % a pharmacodynamic mechanism. An unknown mechanism of interaction was involved in 11 % of drugs. Conclusion Twenty-eight specific drugs were identified as being at high risk for interacting with acenocoumarol in our hospital using an original risk-analysis method. Most analyzed drugs interact with acenocoumarol via a pharmacokinetic mechanism. Actions such as the implementation of alerts in our CPOE system should be specifically developed for these drugs.


    • 18 January 2012
      • Vol. 8  (324) , 96-9

    [New anticoagulants: better knowledge, better prescriptions].

    by F Boehlen, P De Moerloose

    New oral anticoagulants are already or will be soon available. They have shown good efficacy and safety in various studies (prevention and treatment of venous thromboembolism, atrial fibrillation). Their arrival will probably modify the prescription of the current anticoagulant agents. However some precaution should be given in their use pending post marketing studies. Although these new drugs are intended to replace mostly vitamin K antagonists, a place will remain for "old" anticoagulants during the next years.